Medical Marijuana, Inc. Subsidiary Kannaway® Announces Positive Preliminary Results of Validcare CBD Safety Study
SAN DIEGO, CA, May 18, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary Kannaway® has participated in the industry -led cannabidiol (CBD) Safety Study and that its preliminary results, released this week, are overwhelmingly positive for the safety profile of CBD. The study abstract can be viewed here . Validcare acted as CRO for the study, which was completed on March 22, 2022, and involved 1,061 U.S. participants and 17 CBD companies, including Kannaway®. All product companies supplied certificates of analysis (COAs) which were confirmed by third-party labs to ensure product label accuracy. These new results will provide the FDA with the data needed to address its safety concerns...